Vaccine Therapy in Treating Patients With Refractory Stage IV Cancer
Completed · Phase 1
Conditions studied: Unspecified Adult Solid Tumor, Protocol Specific
In brief
RATIONALE: Vaccines made from a person's white blood cells mixed with peptides may make the body build an immune response to kill cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with refractory stage IV cancer.
Key facts
- Study ID
- NCT00057915
- Run by
- Duke University
- People needed
- 4
- Starts
- 2003-09-01
- Expected to finish
- 2006-09-01
- Last updated by the study team
- 2014-09-08
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Duke Comprehensive Cancer Center — Durham, North Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.